Get insights on DeepQure and its HyperQure renal denervation system directly from the company's co-founders, Mr Chan-Ho Park and Dr Chang Wook Jeong.

Explore the differences between catheter-based and extravascular RDN in this deep dive into these approaches

Understand the reasons for the market's keen interest in renal denervation technologies today, and how this field is shaping up to offer an alternative to drugs in hypertension management

Renal denervation involves different clinicians with different specialties. Learn about the clinical pathway for RDN from Dr Chang-Wook Jeong, co-founder and Chief Medical Officer of DeepQure.

Hypertension treatment is primarily based on pharmaceuticals currently. Renal denervation, however, is shaping up to be a viable alternative. Learn how they relate to each other in this comparison.

Learn all about hypertension, its causes and management, as well as how renal denervation is fast becoming a mainstream treatmentt for the condition.